irinotecan accord 20 mg/ml inf. sol. (conc.) i.v. vial
accord healthcare b.v. - irinotecan hydrochloride trihydrate 20 mg/ml - concentrate for solution for infusion - 20 mg/ml - irinotecan hydrochloride trihydrate 20 mg/ml - topoisomerase 1 (top1) inhibitors
irinotecan accord 20 mg/ml inf. sol. (conc.) i.v. vial
accord healthcare b.v. - irinotecan hydrochloride trihydrate 20 mg/ml - concentrate for solution for infusion - 20 mg/ml - irinotecan hydrochloride trihydrate 20 mg/ml - topoisomerase 1 (top1) inhibitors
irinotecan accord 20 mg/ml inf. sol. (conc.) i.v. vial
accord healthcare b.v. - irinotecan hydrochloride trihydrate 20 mg/ml - concentrate for solution for infusion - 20 mg/ml - irinotecan hydrochloride trihydrate 20 mg/ml - topoisomerase 1 (top1) inhibitors
irinotecan accord 20 mg/ml inf. sol. (conc.) i.v. vial
accord healthcare b.v. - irinotecan hydrochloride trihydrate 20 mg/ml - concentrate for solution for infusion - 20 mg/ml - irinotecan hydrochloride trihydrate 20 mg/ml - topoisomerase 1 (top1) inhibitors
irinotecan hydrochloride
accord healthcare limited - irinotecan hydrochloride trihydrate - concentrate for soln for inf - 20 mg/ml - irinotecan
irinotecan hydrochloride
hospira uk limited - irinotecan hydrochloride trihydrate - concentrate for soln for inf - 20 mg/ml - irinotecan
hospira irinotecan hydrochloride trihydrate trihydrate for injection 500 mg/25 ml vial
hospira australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection, solution - excipient ingredients: lactic acid; sorbitol; water for injections; sodium hydroxide; hydrochloric acid - irinotecan hydrochloride trihydrate is indicated as: - a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum; - a single agent for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-fluorouracil-based therapy.
hospira irinotecan hydrochloride trihydrate trihydrate for injection 100 mg/5 ml vial
hospira australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection, solution - excipient ingredients: lactic acid; sorbitol; water for injections; sodium hydroxide; hydrochloric acid - irinotecan hydrochloride trihydrate is indicated as: - a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum; - a single agent for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-fluorouracil-based therapy.
irinotecan accord irinotecan hydrochloride trihydrate 100 mg/5 ml concentrated injection vial
accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: hydrochloric acid; lactic acid; sodium hydroxide; water for injections; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.
irinotecan accord irinotecan hydrochloride trihydrate 40 mg/2 ml concentrated injection vial
accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid; sorbitol; lactic acid - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.